12 Month Price Forecast For KYTX
Distance to KYTX Price Forecasts
KYTX Price Momentum
๐ค Considering Kyverna (KYTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 3:56 AM UTC
KYTX Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, KYTX has a consensus that is bullish. The median price target is $24.50, with forecasts ranging from $6.00 to $40.00. Currently, there are 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With KYTX currently trading at $3.00, the median price forecast suggests a 716.7% upside. The most optimistic forecast comes from Michael Ulz at Morgan Stanley, projecting a 1,233.3% upside, while Mitchell Kapoor at HC Wainwright & Co. provides the most conservative target, suggesting a 100.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KYTX Analyst Consensus
KYTX Price Target Range
Latest KYTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KYTX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 20, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $6.00 |
Nov 15, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $24.00 |
Oct 10, 2024 | UBS | Trung Huynh | Buy | Initiates | $13.00 |
Sep 19, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $7.00 |
Aug 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $7.00 |
Jul 31, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $33.00 |
Jul 16, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $8.00 |
Jul 3, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Initiates | $8.00 |
Mar 4, 2024 | Morgan Stanley | Michael Ulz | Overweight | Initiates | $40.00 |
Mar 4, 2024 | JP Morgan | Brian Cheng | Overweight | Initiates | $39.00 |
Stocks Similar to Kyverna Therapeutics, Inc. Common Stock
The following stocks are similar to Kyverna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial Data
Kyverna Therapeutics, Inc. Common Stock has a market capitalization of $134.26M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -59.6%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Kyverna Therapeutics, Inc. Common Stock (KYTX) Company Overview
About Kyverna Therapeutics, Inc. Common Stock
Develops cell therapies for autoimmune diseases.
Kyverna Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of autologous and allogeneic CAR T-cell therapies. It generates revenue through licensing and collaboration agreements with other biotechnology companies, which support its research and development efforts for various autoimmune diseases.
The company's lead product, KYV-101, is currently in Phase I and II clinical trials for lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Additionally, KYV-201 is under development for multiple autoimmune diseases in the preclinical stage. Kyverna was formerly known as BAIT Therapeutics and changed its name in October 2019, highlighting its commitment to innovative therapies in the autoimmune space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
96
CEO
Mr. Warner Biddle
Country
United States
IPO Year
N/A
Website
kyvernatx.comKyverna Therapeutics, Inc. Common Stock (KYTX) Latest News & Analysis
A class action lawsuit has been filed against Kyverna Therapeutics, Inc. (NASDAQ:KYTX) for alleged federal securities law violations related to its February 2024 IPO.
A class action lawsuit against Kyverna Therapeutics could indicate potential legal and financial risks, impacting investor confidence and stock performance following its IPO.
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - KYTX
1 day agoKyverna Therapeutics, Inc. (NASDAQ:KYTX) investors who experienced losses may explore recovery options under federal securities laws. More information is available via the provided link.
The announcement of a potential lawsuit for Kyverna Therapeutics indicates possible legal and financial risks, which may affect stock performance and investor confidence.
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
1 day agoInvestors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who have incurred losses may explore potential recovery options under federal securities laws. More details are available via the provided link.
The news indicates potential legal issues for Kyverna Therapeutics, which could affect its stock performance and investor confidence, signaling a need for investors to reassess their holdings.
Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who experienced losses may explore potential recovery options under federal securities laws. Further details are available through a provided link.
A potential lawsuit for Kyverna Therapeutics may indicate underlying issues, affecting stock performance and investor confidence, which could lead to volatility.
Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who experienced losses may explore potential recovery options under federal securities laws. More info is available via the provided link.
A potential lawsuit indicates investor dissatisfaction and possible financial instability for Kyverna Therapeutics, which may affect its stock price and investor sentiment.
Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who experienced losses may explore potential recovery options under federal securities laws. More information is available through a specified link.
A potential lawsuit against Kyverna Therapeutics may indicate problems within the company, affecting stock performance and investor confidence. Legal issues can lead to volatility and loss recovery opportunities.
Frequently Asked Questions About KYTX Stock
What is Kyverna Therapeutics, Inc. Common Stock's (KYTX) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Kyverna Therapeutics, Inc. Common Stock (KYTX) has a median price target of $24.50. The highest price target is $40.00 and the lowest is $6.00.
Is KYTX stock a good investment in 2025?
According to current analyst ratings, KYTX has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KYTX stock?
Wall Street analysts predict KYTX stock could reach $24.50 in the next 12 months. This represents a 716.7% increase from the current price of $3.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kyverna Therapeutics, Inc. Common Stock's business model?
Kyverna Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of autologous and allogeneic CAR T-cell therapies. It generates revenue through licensing and collaboration agreements with other biotechnology companies, which support its research and development efforts for various autoimmune diseases.
What is the highest forecasted price for KYTX Kyverna Therapeutics, Inc. Common Stock?
The highest price target for KYTX is $40.00 from Michael Ulz at Morgan Stanley, which represents a 1,233.3% increase from the current price of $3.00.
What is the lowest forecasted price for KYTX Kyverna Therapeutics, Inc. Common Stock?
The lowest price target for KYTX is $6.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 100.0% increase from the current price of $3.00.
What is the overall KYTX consensus from analysts for Kyverna Therapeutics, Inc. Common Stock?
The overall analyst consensus for KYTX is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are KYTX stock price projections?
Stock price projections, including those for Kyverna Therapeutics, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.